Literature DB >> 26136988

Effect of Helicobacter pylori on cyclooxygenase-2 and inducible nitric oxide synthase in patients with gastric precancerous lesions and its clinical significance.

Hui Zhang1, Chunsheng Ding1, Zhimin Suo1, Yuhua Kang1.   

Abstract

The aim of this study was to investigate the effect of Helicobacter pylori (Hp) on cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) levels in patients with gastric precancerous lesions and its clinical significance. A total of 114 patients with gastric precancerous lesions, 57 whom were positive for Hp (observation group) and 57 of whom were negative for Hp (control group), were selected for the study. The mRNA levels of COX-2 and iNOS in the gastric precancerous lesion tissue from the two groups of patients were analyzed through the reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The protein expression levels of COX-2 and iNOS were analyzed using western blotting and an iNOS kit, respectively. In addition, normal human gastric mucosal GES-1 cells were cultured in vitro and stimulated by Hp for 3, 6, 9 and 12 h. The variations in the mRNA and protein levels of COX-2 and iNOS were then analyzed via RT-qPCR and western blotting. Compared with the control group, the mRNA levels of COX-2 and iNOS in the gastric tissue from the observation group were significantly increased (P<0.05). Furthermore, the expression level of COX-2 and iNOS protein in the gastric tissue from the observation group was significantly higher than that in the tissue from the control group (P<0.05). In vitro analysis showed that the COX-2 and iNOS mRNA and protein levels were significantly increased in the Hp-stimulated normal human gastric mucosal GES-1 cells compared with those in the unstimulated cells. Furthermore, the effect was time-dependent (P<0.05). In conclusion, COX-2 and iNOS are the main inflammatory markers. Hp can induce high expression levels of COX-2 and iNOS in gastric precancerous lesion tissue, which may be associated with the occurrence and development of gastric precancerous lesions.

Entities:  

Keywords:  Helicobacter pylori; cyclooxygenase-2; gastric precancerous lesions; inducible nitric oxide synthase

Year:  2015        PMID: 26136988      PMCID: PMC4473662          DOI: 10.3892/etm.2015.2387

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  18 in total

1.  A clinical study of weining granules in the treatment of gastric precancerous lesions.

Authors:  Xin Deng; Zhen-wei Liu; Fa-sheng Wu; Long-hua Li; Jia Liang
Journal:  J Tradit Chin Med       Date:  2012-06       Impact factor: 0.848

Review 2.  Immunotherapy for gastric premalignant lesions and cancer.

Authors:  Valerio Zorzetto; Gemma Maddalo; Daniela Basso; Fabio Farinati
Journal:  Immunotherapy       Date:  2012-06       Impact factor: 4.196

Review 3.  Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.

Authors:  Arthur J Chu; Ta-Hsu Chou; Ben D Chen
Journal:  Front Biosci       Date:  2004-09-01

4.  Risk of advanced gastric precancerous lesions in Helicobacter pylori infected subjects is influenced by ABO blood group and cagA status.

Authors:  Cosmeri Rizzato; Ikuko Kato; Martyn Plummer; Nubia Muñoz; Angelika Stein; Leen Jan van Doorn; Silvia Franceschi; Federico Canzian
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

Review 5.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

Review 6.  Carcinogenesis of Helicobacter pylori.

Authors:  Pelayo Correa; Jeanmarie Houghton
Journal:  Gastroenterology       Date:  2007-08       Impact factor: 22.682

Review 7.  The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage.

Authors:  Aleksandra Szlachcic; Gracjana Krzysiek-Maczka; Robert Pajdo; Aneta Targosz; Marcin Magierowski; Katarzyna Jasnos; Danuta Drozdowicz; Slawomir Kwiecien; Tomasz Brzozowski
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  iNOS-selective inhibitors for cancer prevention: promise and progress.

Authors:  Naveena B Janakiram; Chinthalapally V Rao
Journal:  Future Med Chem       Date:  2012-11       Impact factor: 3.808

9.  Polymorphisms in genes related to bacterial lipopolysaccharide/peptidoglycan signaling and gastric precancerous lesions in a population at high risk for gastric cancer.

Authors:  Ikuko Kato; Federico Canzian; Martyn Plummer; Silvia Franceschi; Leen-Jan van Doorn; Jorge Vivas; Gladys Lopez; Yanhui Lu; Lydie Gioia-Patricola; Richard K Severson; Ann G Schwartz; Nubia Muñoz
Journal:  Dig Dis Sci       Date:  2006-12-14       Impact factor: 3.487

10.  MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.

Authors:  J Zhang; J Luo; J Ni; L Tang; H P Zhang; L Zhang; J F Xu; D Zheng
Journal:  Eur J Histochem       Date:  2014-02-18       Impact factor: 3.188

View more
  2 in total

1.  Improved method for inducing chronic atrophic gastritis in mice.

Authors:  Xian Wei; Xue-Ping Feng; Lu-Yao Wang; Yan-Qiang Huang; Ling-Ling Liang; Xiao-Qiang Mo; Hong-Yu Wei
Journal:  World J Gastrointest Oncol       Date:  2019-12-15

Review 2.  From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Authors:  Giovanni Vitale; Alessandra Dicitore; Luigi Barrea; Emilia Sbardella; Paola Razzore; Severo Campione; Antongiulio Faggiano; Annamaria Colao; Manuela Albertelli; Barbara Altieri; Filomena Bottiglieri; Federica De Cicco; Sergio Di Molfetta; Giuseppe Fanciulli; Tiziana Feola; Diego Ferone; Francesco Ferraù; Marco Gallo; Elisa Giannetta; Federica Grillo; Erika Grossrubatscher; Elia Guadagno; Valentina Guarnotta; Andrea M Isidori; Andrea Lania; Andrea Lenzi; Fabio Lo Calzo; Pasquale Malandrino; Erika Messina; Roberta Modica; Giovanna Muscogiuri; Luca Pes; Genoveffa Pizza; Riccardo Pofi; Giulia Puliani; Carmen Rainone; Laura Rizza; Manila Rubino; Rosa Maria Ruggieri; Franz Sesti; Mary Anna Venneri; Maria Chiara Zatelli
Journal:  Rev Endocr Metab Disord       Date:  2020-09-15       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.